You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 8, 2024

ELTROMBOPAG OLAMINE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Eltrombopag Olamine patents expire, and what generic alternatives are available?

Eltrombopag Olamine is a drug marketed by Annora Pharma and is included in one NDA.

The generic ingredient in ELTROMBOPAG OLAMINE is eltrombopag olamine. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the eltrombopag olamine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Eltrombopag Olamine

A generic version of ELTROMBOPAG OLAMINE was approved as eltrombopag olamine by ANNORA PHARMA on April 18th, 2024.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ELTROMBOPAG OLAMINE?
  • What are the global sales for ELTROMBOPAG OLAMINE?
  • What is Average Wholesale Price for ELTROMBOPAG OLAMINE?
Drug patent expirations by year for ELTROMBOPAG OLAMINE
Recent Clinical Trials for ELTROMBOPAG OLAMINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
NovartisPhase 2
National Taiwan University HospitalPhase 2
Second Affiliated Hospital of Guangzhou Medical UniversityPhase 4

See all ELTROMBOPAG OLAMINE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for ELTROMBOPAG OLAMINE
Paragraph IV (Patent) Challenges for ELTROMBOPAG OLAMINE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
PROMACTA KIT For Oral Suspension eltrombopag olamine 12.5 mg/packet and 25 mg/packet 207027 1 2022-04-22
PROMACTA Tablets eltrombopag olamine 12.5 mg and 25 mg 022291 1 2014-02-04
PROMACTA Tablets eltrombopag olamine 50 mg and 75 mg 022291 1 2014-01-07

US Patents and Regulatory Information for ELTROMBOPAG OLAMINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Annora Pharma ELTROMBOPAG OLAMINE eltrombopag olamine FOR SUSPENSION;ORAL 216620-001 Apr 18, 2024 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Annora Pharma ELTROMBOPAG OLAMINE eltrombopag olamine FOR SUSPENSION;ORAL 216620-002 Apr 18, 2024 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.